SCRI Oncology Partners reposted this
Today is a day that brings mixed emotions as I reflect on my last day as a team member at the Swedish Cancer Institute. It has been an honor and privilege to work alongside many talented, kind, and dedicated individuals in my time at Swedish. Together our team has achieved many important milestones including establishing and rapidly expanding SCI’s cellular therapy program, building one of the West Coast’s largest hematology clinical research programs, and improving access to specialized blood cancer care for patients all around the Pacific Northwest. Along the way we have helped shape the standards for how blood cancers are cared for globally. I am deeply grateful for the opportunity to serve the PNW community and will carry forward valuable lessons on addressing disparities in patient outcomes. With those lessons in mind, I am extremely excited to soon join the Sarah Cannon Research Institute (SCRI) as the Director for Lymphoma Research and join the SCRI Oncology Partners practice in Nashville. Advancing the care of patients with Lymphomas and Chronic Lymphocytic Leukemia (CLL) is my passion. Collectively, lymphomas are the 7th most prevalent cancer with ~90,000 people newly diagnosed with lymphoma in the US each year. CLL is the most common leukemia worldwide with more than 200,000 people living with CLL in the US and more than 20,000 people newly diagnosed with CLL annually. The Sarah Cannon Research Institute is one of the largest oncology clinical research organizations globally and the Sarah Cannon Transplant & Cellular Therapy Network the largest provider of transplant and cellular therapy care in the US. The scale of the Sarah Cannon Cancer Network provides an unparalleled platform from which we can accelerate clinical development of promising new lymphoma and CLL therapies and to improve community-based access to novel therapies for patients living with these diseases. I am humbled and beyond grateful to join the team of world-class cancer researchers at SCRI and to continue the work of improving the treatment options, outcomes, and access to cutting edge care for all patients with Lymphoma and CLL. As I embark on this transition, please feel free to reach out around potential future collaborations!
We are pleased to announce that Dr. Krish Patel has been appointed as the Director of Lymphoma Research at SCRI! In his new role, Dr. Patel will lead our lymphoma research program and will practice at SCRI Oncology Partners in Nashville, starting mid-November. His appointment is a exciting step in strengthening our capacity to advance lymphoma clinical trials and enhancing patient care within our research network. Join us in welcoming Dr. Patel to SCRI! 🔗 Read the full press release: https://lnkd.in/gb2T3niJ #CancerResearch #Lymphoma #Oncology #ClinicalTrials #SCRI